摘要
目的:探讨达格列净治疗2型糖尿病(T2DM)合并冠心病(CHD)患者的效果。方法:选取2020年1月-2021年3月在厦门市第五医院接受治疗的119例T2DM合并CHD患者。根据随机数表法将其分为常规组(59例)与达格列净组(60例)。两组均给予常规CHD用药。常规组给予盐酸二甲双胍缓释片,达格列净组给予达格列净。比较两组治疗前(T_(0))、治疗24周后(T_(1))血糖指标、血脂指标、炎症因子及不良心血管事件。结果:T_(1),两组空腹血糖(FPG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平均较T_(0)下降,且达格列净组FPG、2 h PBG、HbA1c、TC、TG、LDL-C水平均低于常规组,差异有统计学意义(P<0.05)。T_(1),两组白细胞介素-6(IL-6),C反应蛋白(CRP)水平均较T_(0)下降,达格列净组IL-6、CRP水平均低于常规组,差异有统计学意义(P<0.05)。达格列净组不良心血管事件发生率低于常规组,差异有统计学意义(P<0.05)。结论:达格列净对T2DM合并CHD患者的血糖、血脂、炎症因子均具有调节作用,有助于降低不良心血管事件风险。
Objective:To investigate the effects of Dapagliflozin in the treatment of patients with diabetes mellitus type 2(T2DM)complicated with coronary heart disease(CHD).Method:A total of 119 patients with T2DM complicated with CHD who were treated in Xiamen Fifth Hospital from January 2020 to March 2021 were selected.According to random number table method,they were divided into conventional group(59 cases)and Dapagliflozin group(60 cases).Both groups were given conventional CHD medication.The conventional group was given Metformin Hydrochloride Sustained-release Tablets,and the Dapagliflozin group was given Dapagliflozin.Blood glucose index,blood lipid index,inflammatory factors before treatment(T_(0))and after 24 weeks of treatment(T_(1))and adverse cardiovascular events were compared between the two groups.Result:At T_(1),fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PBG),glycated hemoglobin(HbA1c),total cholesterol(TC),triglyceride(TG)and low density lipoprotein cholesterol(LDL-C)levels in both groups were lower than those at T_(0),the levels of FPG,2 h PBG,HbA1c,TC,TG and LDL-C in Dapagliflozin group were lower than those in conventional group,the differences were statistically significant(P<0.05).At T_(1),the levels of interleukin-6(IL-6)and C-reactive protein(CRP)in both groups were decreased compared with those at T_(0),and the levels of IL-6 and CRP in Dapagliflozin group were lower than those in conventional group,the differences were statistically significant(P<0.05).The incidence of adverse cardiovascular events in Dapagliflozin group was lower than that in the conventional group,and the difference was statistically significant(P<0.05).Conclusion:Dapagliflozin can regulate blood glucose,blood lipid and inflammatory factors in patients with T2DM complicated with and CHD,which is helpful to reduce the risk of adverse cardiovascular events.
作者
钟璐红
邹良能
ZHONG Luhong;ZOU Liangneng(Xiamen Fifth Hospital,Xiamen 361000,China;不详)
出处
《中外医学研究》
2023年第22期29-32,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
达格列净
2型糖尿病
冠心病
不良心血管事件
Dapagliflozin
Diabetes mellitus type 2
Coronary heart disease
Adverse cardiovascular events
